You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

7 Results
Drug
Jan 2018
Guidelines and Advice
Status: Current
ID: GL 8-11
Jan 2018
Statistical Reports
Regimen
Intent: Curative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
New
Apr 2026
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Adjuvant
New
Apr 2026